Cargando…
Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma
In this study, we examined ERCC1 and BRCA1 expression and clinical outcome of 201 phase-III-IV nasopharyngeal carcinoma patients who were treated with cisplatin-based induced chemotherapy and concurrent radiochemotherapy. The chemotherapy response rate of BRCA1(–) and BRCA1(+) patients was 73.6% and...
Autores principales: | Xu, Shan, Yu, Yanxin, Rong, Jinfeng, Hu, Defeng, Zhang, LiJun, Fu, Shaozhi, Yang, Hongru, Fan, Juan, Yang, Linglin, Wu, Jingbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458213/ https://www.ncbi.nlm.nih.gov/pubmed/28404895 http://dx.doi.org/10.18632/oncotarget.15565 |
Ejemplares similares
-
Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022) -
Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma
por: Huang, Xue, et al.
Publicado: (2017) -
The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes
por: Kim, Dokyung, et al.
Publicado: (2011) -
DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population
por: Yu, Xian, et al.
Publicado: (2015) -
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)